Remibrutinib - Novartis
Alternative Names: LOU-064; LOU064-NXA; NVP-LOU064-NXALatest Information Update: 25 Jul 2024
At a glance
- Originator Novartis
- Class Amines; Anti-inflammatories; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Ethers; Fluorobenzenes; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic urticaria; Multiple sclerosis
- Phase II Hidradenitis suppurativa; Peanut hypersensitivity
- Discontinued Asthma; Atopic dermatitis; Sjogren's syndrome
Most Recent Events
- 18 Jul 2024 Novartis plans to submit regulatory applications for Chronic urticaria in 2025
- 31 May 2024 Updated pooled efficacy and adverse events data from the REMIX-1 and REMIX-2 trials in Chronic urticaria released by Novartis
- 13 May 2024 Phase-III clinical trials in Chronic-urticaria (In children, In adolescents) (PO), before May 2024 (Novartis pipeline, May 2024)